Significant Differences in Effects of Sitagliptin Treatment on Body Weight and Lipid Metabolism Between Obese and Non-Obese Patients With Type 2 Diabetes

Hisayuki Katsuyama, Hiroki Adachi, Hidetaka Hamasaki, Sumie Moriyama, Akahito Sako, Hidekatsu Yanai

Abstract


Background: We previously reported that HbA1c levels and body weight significantly decreased by 0.6% and by 0.8 kg, respectively, at 6 months after sitagliptin treatment started. We found a significant and negative correlation between change in body weight and body mass index (BMI) at baseline.

Methods: We retrospectively sub-analyzed effects of 6-month treatment with sitagliptin on glucose and lipid metabolism, blood pressure, body weight and renal function in patients with type 2 diabetes, by dividing 173 type 2 diabetic subjects into obese group (BMI is greater than or equal to 25) and non-obese group (BMI < 25).

Results: At baseline, obese group was significantly younger than non-obese group. Diastolic blood pressure, low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG), and estimated glomerular filtration rate (eGFR) in obese group were significantly higher than in non-obese group. Serum high-density lipoprotein-cholesterol (HDL-C) in obese group was significantly lower than in non-obese group. At 6 months after the start of sitagliptin use, body weight significantly decreased in obese group, while body weight did not change in non-obese group. HbA1c significantly decreased in both groups. Serum HDL-C significantly decreased in obese group, while serum HDL-C did not change in non-obese group. Serum TG significantly decreased in obese group, while serum TG significantly increased in non-obese group. Change in serum TG was significantly and inversely correlated with BMI at baseline.

Conclusions: We found significant differences in effects of sitagliptin treatment on body weight and lipid metabolism between obese and non-obese patients with type 2 diabetes. Sitagliptin improved HbA1c regardless of the existence of obesity. In obese people, sitagliptin significantly reduced body weight and serum TG. Sitagliptin reduced serum TG in a baseline-BMI-dependent manner.




J Endocrinol Metab. 2014;4(5-6):136-142
doi: http://dx.doi.org/10.14740/jem243w


Keywords


Body weight; HbA1c; Obesity; Sitagliptin; Triglyceride

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.